CTOs on the Move

WCG Clinical Services

www.wcgclinical.com

 
WCG is the world`s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG`s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.wcgclinical.com
  • 212 Carnegie Center Suite 301
    Princeton, NJ USA 08540
  • Phone: 609.945.0101

Executives

Name Title Contact Details
Ken Hyers
Senior Director IT Architecture Services Profile
Paul Mancinelli
Chief Technology Officer Profile

Similar Companies

Hyaluron

Hyaluron is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bryn Pharma

Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.

Sertech

Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

EMD Electronics

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.